Addition of pembrolizumab to chemotherapy extends survival in advanced lung cancer

Introducing first-line immunotherapy could benefit long-term outcomes in advanced non-small-cell lung cancer (NSCLC), a study has revealed.
Source: Clinical Pharmacist - Category: Drugs & Pharmacology Source Type: research